Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Clinical Professor Russell S. Scott

BMedSc MB ChB(Otago) PhD(Monash) FRACP

Lipids and Diabetes Research
Christchurch Hospital
Private Bag 4710
Christchurch
New Zealand

Email russell.scott@cdhb.govt.nz

Current Roles

  • Clinical Professor of Medicine, University of Otago, Christchurch, New Zealand
  • Director, Lipid and Diabetes Research, Christchurch
  • Christchurch Physician in Charge, Lipid Disorders and Cardiovascular Prevention, Canterbury District Health Board
  • Physician, Diabetes Services, Canterbury District Health Board
  • Physician, Internal Medicine, Canterbury District Health Board
  • Consultant, MedLab South

Research Interests

  • Prevention and treatment of type 1 Diabetes Mellitus
  • Adipocyte function and Insulin resistance
  • Lipid disorders and CVD
  • Endothelial function and endocrine regulation
  • Diabetes Epidemiology and health outcomes

Top 10 Publications

  • Scott R.S. and Burger H.G. Inhibin is absent from azoospermic semen of infertile men. In Nature 285: 246 247 (1980). Also profiled in Yearbook of Endocrinology, Mosby (1981).
  • Scott R.S., Brown L.J., Darlow B.A., Forbes L.V. and Moore M.P. Temporal variations in incidence of IDDM in New Zealand. In Diabetes Care 15:895-899 (1992).
  • Forbes L.V., Scott R.S., Brown L.J. and Darlow B.A. Immunogenetic, clinical and demographic characterisation of childhood type I diabetes in New Zealand. In Diabetes Care 18: 1428-1433 (1995).
  • Florkowski C.M., Scott R.S., Moir C.L. and Graham P.J. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. In Diabetic Medicine 15:386-392 (1998).
  • Willis J.A., Scott R.S., Darlow B.A, Lewy H., Ashkenazi I., Laron Z., Seasonality of Birth and Onset of Clinical Disease in Children and Adolescents (0 � 19 years) with Type 1 Diabetes Mellitus in Canterbury, New Zealand. In Journal of Pediatric Endocrinology & Metabolism, 15: 645 � 647 (2002). Also, subject of editorial comment by Z Laron in Journal of Pediatric Endocrinology & Metabolism 15:573-575 (2002).
  • Phillips P., Karrasch J., Scott R., Wilson D., Moses R. Acarbose improves glycaemic control in overweight Type 2 diabetic patients insufficiently treated with metformin. In Diabetes Care, 26:269-273 (2003).
  • Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott R.S. The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. In Diabetologia 47: 1838-1846 (2004).
  • The FIELD Study Investigators ( R. Scott, writing committee and Executive Committee member). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology Dec 1;3:9, (2004)
  • Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott R.S, Frampton CM. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179:201-6 (2005)
  • Scott RS, Best J, Forder P, Taskinen M.R., Simes J, Barter P, Keech A (The FIELD study investigators). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate. Cardiovascular Diabetology Aug 22;4:13 ( 2005)

Publications

Loading publications